Aspirin resistance: Focus on clinical endpoints

Gabriella Pusch, G. Fehér, Katalin Kotai, Antal Tibold, B. Gasztonyi, Andrea Feher, E. Papp, Geza Lupkovics, L. Szapáry

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

INTRODUCTION: Via its antiplatelet effect, aspirin reduces the odds of an arterial thrombotic event in high-risk patients by approximately 25%. However, 10% to 20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up. Nevertheless, the effectiveness of aspirin has been questioned by the emergence of the concept of aspirin resistance, which has been introduced as an explanation of the fact that a considerable proportion of patients treated with aspirin exhibit normal platelet function. OBJECTIVES AND METHODS: We systematically reviewed all available evidence till March 2008 on prevalence of aspirin resistance and its association with clinical outcome. We also collected articles showing the possible way of treatment. CONCLUSION: Analyzing the data of different laboratory methods aspirin resistance seems to be associated with poor clinical outcome, although currently no standardized or widely accepted definition of aspirin resistance exists. The widely used laboratory methods might not be comparable with each other; therefore, specific treatment recommendations for patients who exhibit high platelet reactivity during aspirin therapy or who have poor platelet inhibition by aspirin are not established.

Original languageEnglish
Pages (from-to)475-484
Number of pages10
JournalJournal of Cardiovascular Pharmacology
Volume52
Issue number6
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Aspirin
Blood Platelets
Therapeutics

Keywords

  • Antiplatelet agent
  • Aspirin
  • Aspirin resistance
  • Cardiovascular outcome
  • Platelet aggregation

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Aspirin resistance : Focus on clinical endpoints. / Pusch, Gabriella; Fehér, G.; Kotai, Katalin; Tibold, Antal; Gasztonyi, B.; Feher, Andrea; Papp, E.; Lupkovics, Geza; Szapáry, L.

In: Journal of Cardiovascular Pharmacology, Vol. 52, No. 6, 12.2008, p. 475-484.

Research output: Contribution to journalArticle

Pusch, Gabriella ; Fehér, G. ; Kotai, Katalin ; Tibold, Antal ; Gasztonyi, B. ; Feher, Andrea ; Papp, E. ; Lupkovics, Geza ; Szapáry, L. / Aspirin resistance : Focus on clinical endpoints. In: Journal of Cardiovascular Pharmacology. 2008 ; Vol. 52, No. 6. pp. 475-484.
@article{ab36fdb1350a4945912239c509ef69b1,
title = "Aspirin resistance: Focus on clinical endpoints",
abstract = "INTRODUCTION: Via its antiplatelet effect, aspirin reduces the odds of an arterial thrombotic event in high-risk patients by approximately 25{\%}. However, 10{\%} to 20{\%} of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up. Nevertheless, the effectiveness of aspirin has been questioned by the emergence of the concept of aspirin resistance, which has been introduced as an explanation of the fact that a considerable proportion of patients treated with aspirin exhibit normal platelet function. OBJECTIVES AND METHODS: We systematically reviewed all available evidence till March 2008 on prevalence of aspirin resistance and its association with clinical outcome. We also collected articles showing the possible way of treatment. CONCLUSION: Analyzing the data of different laboratory methods aspirin resistance seems to be associated with poor clinical outcome, although currently no standardized or widely accepted definition of aspirin resistance exists. The widely used laboratory methods might not be comparable with each other; therefore, specific treatment recommendations for patients who exhibit high platelet reactivity during aspirin therapy or who have poor platelet inhibition by aspirin are not established.",
keywords = "Antiplatelet agent, Aspirin, Aspirin resistance, Cardiovascular outcome, Platelet aggregation",
author = "Gabriella Pusch and G. Feh{\'e}r and Katalin Kotai and Antal Tibold and B. Gasztonyi and Andrea Feher and E. Papp and Geza Lupkovics and L. Szap{\'a}ry",
year = "2008",
month = "12",
doi = "10.1097/FJC.0b013e31818eee5f",
language = "English",
volume = "52",
pages = "475--484",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Aspirin resistance

T2 - Focus on clinical endpoints

AU - Pusch, Gabriella

AU - Fehér, G.

AU - Kotai, Katalin

AU - Tibold, Antal

AU - Gasztonyi, B.

AU - Feher, Andrea

AU - Papp, E.

AU - Lupkovics, Geza

AU - Szapáry, L.

PY - 2008/12

Y1 - 2008/12

N2 - INTRODUCTION: Via its antiplatelet effect, aspirin reduces the odds of an arterial thrombotic event in high-risk patients by approximately 25%. However, 10% to 20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up. Nevertheless, the effectiveness of aspirin has been questioned by the emergence of the concept of aspirin resistance, which has been introduced as an explanation of the fact that a considerable proportion of patients treated with aspirin exhibit normal platelet function. OBJECTIVES AND METHODS: We systematically reviewed all available evidence till March 2008 on prevalence of aspirin resistance and its association with clinical outcome. We also collected articles showing the possible way of treatment. CONCLUSION: Analyzing the data of different laboratory methods aspirin resistance seems to be associated with poor clinical outcome, although currently no standardized or widely accepted definition of aspirin resistance exists. The widely used laboratory methods might not be comparable with each other; therefore, specific treatment recommendations for patients who exhibit high platelet reactivity during aspirin therapy or who have poor platelet inhibition by aspirin are not established.

AB - INTRODUCTION: Via its antiplatelet effect, aspirin reduces the odds of an arterial thrombotic event in high-risk patients by approximately 25%. However, 10% to 20% of patients with an arterial thrombotic event who are treated with aspirin have a recurrent arterial thrombotic event during long-term follow-up. Nevertheless, the effectiveness of aspirin has been questioned by the emergence of the concept of aspirin resistance, which has been introduced as an explanation of the fact that a considerable proportion of patients treated with aspirin exhibit normal platelet function. OBJECTIVES AND METHODS: We systematically reviewed all available evidence till March 2008 on prevalence of aspirin resistance and its association with clinical outcome. We also collected articles showing the possible way of treatment. CONCLUSION: Analyzing the data of different laboratory methods aspirin resistance seems to be associated with poor clinical outcome, although currently no standardized or widely accepted definition of aspirin resistance exists. The widely used laboratory methods might not be comparable with each other; therefore, specific treatment recommendations for patients who exhibit high platelet reactivity during aspirin therapy or who have poor platelet inhibition by aspirin are not established.

KW - Antiplatelet agent

KW - Aspirin

KW - Aspirin resistance

KW - Cardiovascular outcome

KW - Platelet aggregation

UR - http://www.scopus.com/inward/record.url?scp=59449107938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59449107938&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e31818eee5f

DO - 10.1097/FJC.0b013e31818eee5f

M3 - Article

C2 - 19034037

AN - SCOPUS:59449107938

VL - 52

SP - 475

EP - 484

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 6

ER -